keyword
MENU ▼
Read by QxMD icon Read
search

Angiotensin receptor blocker

keyword
https://www.readbyqxmd.com/read/28915854/medical-therapy-following-hospitalization-for-heart-failure-with-reduced-ejection-fraction-and-association-with-discharge-to-long-term-care-a-cross-sectional-analysis-of-the-reasons-for-geographic-and-racial-differences-in-stroke-regards-population
#1
Emily B Levitan, Melissa K Van Dyke, Ligong Chen, Raegan W Durant, Todd M Brown, J David Rhodes, Olusola Olubowale, Oluwole Muyiwa Adegbala, Meredith L Kilgore, Justin Blackburn, Karen C Albright, Monika M Safford
BACKGROUND: Less intensive treatment for heart failure with reduced ejection fraction (HFrEF) may be appropriate for patients in long-term care settings because of limited life expectancy, frailty, comorbidities, and emphasis on quality of life. METHODS: We compared treatment patterns between REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants discharged to long-term care versus home following HFrEF hospitalizations. We examined medical records and Medicare pharmacy claims for 147 HFrEF hospitalizations among 80 participants to obtain information about discharge disposition and medication prescriptions and fills...
September 16, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28911306/management-of-blood-pressure-and-heart-rate-in-patients-with-diabetes-mellitus
#2
Ioanna Gouni-Berthold, Ruth Hanssen, Lisa Ravarani, Heiner K Berthold
BACKGROUND: In patients with diabetes mellitus (DM) there is a clear association between blood pressure (BP) levels and macrovascular and microvascular complications. However, the BP targets that need to be achieved for optimal outcomes remain controversial. METHODS: The purpose of this narrative review is to discuss BP targets and management in patients with DM. The subject of elevated heart rate, which has been associated with mortality in many populations, and which is observed in some patients with DM will also be addressed...
June 8, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28905299/use-of-antihypertensive-drugs-and-risk-of-malignant-melanoma-a-meta-analysis-of-observational-studies
#3
REVIEW
Huilin Tang, Shuangshuang Fu, Suodi Zhai, Yiqing Song, Jiali Han
INTRODUCTION: Several antihypertensive drugs are photosensitizing and may promote the development of malignant melanoma (MM), but evidence remains inconsistent. We sought to quantify the association between use of antihypertensive drugs and MM risk. METHODS: We systematically searched PubMed, Embase, and CENTRAL from inception to August 17, 2017 to identify observational studies that reported the MM risk associated with the use of antihypertensive drugs. A random-effects meta-analysis was used to estimate the odds ratio (OR) with 95% confidence interval (CI)...
September 13, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28904068/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-established-cardiovascular-disease-and-chronic-kidney-disease
#4
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis T George, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman
Background -Empagliflozin, a sodium glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME(®) trial. Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease...
September 13, 2017: Circulation
https://www.readbyqxmd.com/read/28899928/treatment-of-hypertension-by-increasing-impaired-endothelial-trpv4-kca2-3-interaction
#5
Dongxu He, Qiongxi Pan, Zhen Chen, Chunyuan Sun, Peng Zhang, Aiqin Mao, Yaodan Zhu, Hongjuan Li, Chunxiao Lu, Mingxu Xie, Yin Zhou, Daoming Shen, Chunlei Tang, Zhenyu Yang, Jian Jin, Xiaoqiang Yao, Bernd Nilius, Xin Ma
The currently available antihypertensive agents have undesirable adverse effects due to systemically altering target activity including receptors, channels, and enzymes. These effects, such as loss of potassium ions induced by diuretics, bronchospasm by beta-blockers, constipation by Ca(2+) channel blockers, and dry cough by ACEI, lead to non-compliance with therapies (Moser, 1990). Here, based on new hypertension mechanisms, we explored a new antihypertensive approach. We report that transient receptor potential vanilloid 4 (TRPV4) interacts with Ca(2+)-activated potassium channel 3 (KCa2...
September 12, 2017: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/28899351/association-of-plasma-potassium-with-mortality-and-end-stage-kidney-disease-in-patients-with-chronic-kidney-disease-under-nephrologist-care-the-nephrotest-study
#6
Sandra Wagner, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann, François Vrtovsnik, Eric Thervet, Jean-Jacques Boffa, Ziad A Massy, Bénédicte Stengel, Patrick Rossignol
BACKGROUND: Low and high blood potassium levels are common and were both associated with poor outcomes in patients with chronic kidney disease (CKD). Whether such relationships may be altered in CKD patients receiving optimized nephrologist care is unknown. METHODS: NephroTest is a hospital-based prospective cohort study that enrolled 2078 nondialysis patients (mean age: 59 ± 15 years, 66% men) in CKD stages 1 to 5 who underwent repeated extensive renal tests including plasma potassium (PK) and glomerular filtration rate (GFR) measured (mGFR) by (51)Cr-EDTA renal clearance...
September 12, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28889965/losartan-counteracts-the-effects-of-cardiomyocyte-swelling-on-glucose-uptake-and-insulin-receptor-substrate-1-levels
#7
Yamil Gerena, Janice Griselle Lozada, Bryan Jael Collazo, Jarold Méndez-Álvarez, Jennifer Méndez-Estrada, Walmor C De Mello
A growing body of evidence demonstrates an association between Angiotensin II (Ang II) receptor blockers (ARBs) and enhanced glucose metabolism during ischemic heart disease. Despite these encouraging results, the mechanisms responsible for these effects during ischemia remain poorly understood. In this study we investigated the influence of losartan, an AT1 receptor blocker, and secreted Ang II (sAng II) on glucose uptake and insulin receptor substrate (IRS-1) levels during cardiomyocyte swelling. H9c2 cells were differentiated to cardiac muscle and the levels of myogenin, Myosin Light Chain (MLC), and membrane AT1 receptors were measured using flow cytometry...
September 7, 2017: Peptides
https://www.readbyqxmd.com/read/28888268/a-randomized-multicenter-open-label-blinded-end-point-trial-comparing-the-effects-of-spironolactone-to-chlorthalidone-on-left-ventricular-mass-in-patients-with-early-stage-chronic-kidney-disease-rationale-and-design-of-the-spiro-ckd-trial
#8
Manvir K Hayer, Nicola C Edwards, Gemma Slinn, William E Moody, Rick P Steeds, Charles J Ferro, Anna M Price, Cecilio Andujar, Mary Dutton, Rachel Webster, David J Webb, Scott Semple, Iain MacIntyre, Vanessa Melville, Ian B Wilkinson, Thomas F Hiemstra, David C Wheeler, Anna Herrey, Margaret Grant, Samir Mehta, Natalie Ives, Jonathan N Townend
BACKGROUND: Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared with placebo in subjects with early-stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. AIM: The aim was to investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure...
September 2017: American Heart Journal
https://www.readbyqxmd.com/read/28886992/study-on-the-effect-of-irbesartan-on-atrial-fibrillation-recurrence-in-kumamoto-atrial-fibrillation-suppression-trial-silk-study
#9
Hiroshige Yamabe, Koichi Kaikita, Toshiyuki Matsumura, Atsushi Iwasa, Junjiro Koyama, Takashi Uemura, Yasuhiro Morikami, Ryusuke Tsunoda, Kenji Morihisa, Kazuteru Fujimoto, Ichiro Kajiwara, Kunihiko Matsui, Kenichi Tsujita, Hisao Ogawa
BACKGROUND: Experimental studies suggest that angiotensin II-receptor blockers can influence atrial remodeling and may prevent atrial fibrillation (AF). Therefore, we hypothesized that irbesartan may prevent the recurrence of AF following either catheter ablation or electrical cardioversion of AF. METHODS: Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto (SILK study) is a prospective, multicenter, randomized, and open-label comparative evaluation of the effects of irbesartan and amlodipine on AF recurrence in hypertensive patients with AF who are scheduled to undergo catheter ablation or electrical cardioversion of AF...
September 5, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28884281/angiotensin-receptor-blockade-by-inhibiting-glial-activation-promotes-hippocampal-neurogenesis-via-activation-of-wnt-%C3%AE-catenin-signaling-in-hypertension
#10
Shahnawaz Ali Bhat, Ruby Goel, Shubha Shukla, Rakesh Shukla, Kashif Hanif
Hypertension is one of the major risk factors for central nervous system (CNS) disorders like stroke and Alzheimer's disease (AD). On the other hand, CNS diseases like AD have been associated with gliosis and impaired neurogenesis. Further, renin angiotensin system (RAS) is intricately associated with hypertension; however, the accumulating evidences suggest that over-activity of RAS may perpetuate the brain inflammation related with AD. Therefore, in the present study, we examined the effect of hypertension and RAS on glial (astrocytes and microglia) activation and hippocampal neurogenesis in a rat model of chronic hypertension...
September 7, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28882562/candesartan-prevents-resiniferatoxin-induced-sensory-small-fiber-neuropathy-in-mice-by-promoting-angiotensin-ii-mediated-at2-receptor-stimulation
#11
Flavien Bessaguet, Aurore Danigo, Laurent Magy, Franck Sturtz, Alexis Desmoulière, Claire Demiot
Sensory defects associated with small-fiber neuropathy (SFN) can lead to profound disabilities. The relationship between the sensory nervous system and modulation of the renin-angiotensin system (RAS) has been described and focused on pain and neurodegeneration in several animal models. We have recently developed an experimental model of functional sensory neuropathy showing thermal hypoalgesia and neuropeptide depletion without nerve fiber degeneration. Here, we aimed to determine whether the modulation of angiotensin II (Ang II) activity could prevent sensory neuropathy induced by RTX...
September 5, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28880266/the-intracellular-angiotensin-system-buffers-deleterious-effects-of-the-extracellular-paracrine-system
#12
Begoña Villar-Cheda, Maria A Costa-Besada, Rita Valenzuela, Emma Perez-Costas, Miguel Melendez-Ferro, Jose L Labandeira-Garcia
The 'classical' renin-angiotensin system (RAS) is a circulating system that controls blood pressure. Local/paracrine RAS, identified in a variety of tissues, including the brain, is involved in different functions and diseases, and RAS blockers are commonly used in clinical practice. A third type of RAS (intracellular/intracrine RAS) has been observed in some types of cells, including neurons. However, its role is still unknown. The present results indicate that in brain cells the intracellular RAS counteracts the intracellular superoxide/H2O2 and oxidative stress induced by the extracellular/paracrine angiotensin II acting on plasma membrane receptors...
September 7, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28880055/resistant-hypertension-an-overview
#13
Roberto Pedrinelli, Giulia Dell' Omo, Giuseppe Ambrosio, Matteo Cameli, Elisabetta Cerbai, Stefano Coiro, Michele Emdin, Riccardo Liga, Rossella Marcucci, Doralisa Morrone, Alberto Palazzuoli, Luigi Padeletti, Ketty Savino
Despite the availability of anti-hypertensive medications with proven efficacy and good tolerability, many hypertensive patients have blood pressure levels(BP) not at the goals set by international societies. Some of these patients are either non-adherent to the prescribed drugs or not optimally treated. However, a proportion, despite adequate treatment, has resistant hypertension(RH) defined as office BP above goal despite the use of ≥3 antihypertensive medications at maximally tolerated doses (one ideally being a diuretic)...
September 5, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28879491/profiling-of-cardio-metabolic-risk-factors-and-medication-utilisation-among-type-ii-diabetes-patients-in-ghana-a-prospective-cohort-study
#14
Eric Adua, Peter Roberts, Samuel Asamoah Sakyi, Francis Agyemang Yeboah, Albert Dompreh, Kwasi Frimpong, Enoch Odame Anto, Wei Wang
BACKGROUND: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively...
September 7, 2017: Clinical and Translational Medicine
https://www.readbyqxmd.com/read/28879040/comparison-of-effects-between-calcium-channel-blocker-and-diuretics-in-combination-with-angiotensin-ii-receptor-blocker-on-24-h-central-blood-pressure-and-vascular-hemodynamic-parameters-in-hypertensive-patients-study-design-for-a-multicenter-double-blinded
#15
Gyu Chul Oh, Hae-Young Lee, Wook Jin Chung, Ho-Joong Youn, Eun-Joo Cho, Ki-Chul Sung, Shung Chull Chae, Byung-Su Yoo, Chang Gyu Park, Soon Jun Hong, Young Kwon Kim, Taek-Jong Hong, Dong-Ju Choi, Min Su Hyun, Jong Won Ha, Young Jo Kim, Youngkeun Ahn, Myeong Chan Cho, Soon-Gil Kim, Jinho Shin, Sungha Park, Il-Suk Sohn, Chong-Jin Kim
BACKGROUND: Hypertension is a risk factor for coronary heart disease and stroke, and is one of the leading causes of death. Although over a billion people are affected worldwide, only half of them receive adequate treatment. Current guidelines on antihypertensive treatment recommend combination therapy for patients not responding to monotherapy, but as the number of pills increase, patient compliance tends to decrease. As a result, fixed-dose combination drugs with different antihypertensive agents have been developed and widely used in recent years...
2017: Clinical Hypertension
https://www.readbyqxmd.com/read/28875506/medications-recommended-for-secondary-prevention-after-first-acute-coronary-syndrome-effectiveness-of-treatment-combinations-in-real-life-setting
#16
Julien Bezin, Olaf H Klungel, Régis Lassalle, Caroline Dureau-Pournin, Nicholas Moore, Antoine Pariente
Long-term effectiveness of Evidence-Based Cardiovascular Medications (EBCMs) indicated after Acute Coronary Syndrome (ACS) needs to be assessed considering the combination effects for these drugs recommended in association. Using a nationwide database, we conducted a cohort study to evaluate the effectiveness of all possible incomplete EBCMs-based combinations as compared to that associating the four recommended EBCMs over up to five years of follow-up. Among the 31,668 patients included, 22.9% had ACS recurrence or died during follow-up...
September 5, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28873219/treatment-effectiveness-in-heart-failure-with-comorbidity-lung-disease-and-kidney-disease
#17
Jerry H Gurwitz, David J Magid, David H Smith, Grace H Tabada, Sue Hee Sung, Larry A Allen, David D McManus, Robert J Goldberg, Mayra Tisminetzky, Alan S Go
OBJECTIVES: To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease. DESIGN: Retrospective cohort study. SETTING: Community. PARTICIPANTS: Individuals with HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF)...
September 5, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28872780/impaired-renal-function-affects-clinical-outcomes-and-management-of-patients-with-heart-failure
#18
Rebeka Jenkins, Lilly Mandarano, Saraniga Gugathas, Juan Carlos Kaski, Lisa Anderson, Debasish Banerjee
AIMS: Inpatients with heart failure and renal impairment have poor outcomes and variable quality of care. We investigate treatment practice and outcomes in an unselected real-world cohort using historical creatinine measurements. METHODS AND RESULTS: Admissions between 1/4/2013 and 30/4/2015 diagnosed at discharge with heart failure were retrospectively analysed. Stages of chronic kidney disease (CKD) and acute kidney injury (AKI) were calculated from creatinine at discharge and 3-12 months before admission...
September 5, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28871813/unspecified-intestinal-malabsorption-in-patients-treated-with-angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers-a-retrospective-analysis-in-primary-care-settings
#19
Nicola de Bortoli, Claudio Ripellino, Nazarena Cataldo, Santino Marchi
OBJECTIVE: To investigate the possible relationship between the use of Angiotensin II Receptor Blockers (ARBs) or Angiotensin-Converting-Enzyme Inhibitors (ACE-i) and unspecified intestinal malabsorption (IM) within the Italian and German real-life context. RESEARCH DESIGN AND METHODS: a retrospective cohort of patients with a new unspecified IM diagnosis during the period 1 January 2010 - 31 December 2013 was extracted from Italian IMS Health Longitudinal Patient Database and German IMS Disease Analyzer...
September 5, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28871467/epigallocatechin-gallate-protects-against-homocysteine-induced-vascular-smooth-muscle-cell-proliferation
#20
Xiao Li Zhan, Xiu Hong Yang, Yan Hong Gu, Li Li Guo, Hui Min Jin
Epigallocatechin gallate (EGCG), a bioactive ingredient of green tea, plays a protective role in the cardiovascular system. Homocysteine (Hcy) is a major risk factor for chronic kidney disease and cardiovascular disease. The present study aimed to investigate the role of EGCG in Hcy-induced proliferation of vascular smooth muscle cells (VSMCs) and its underlying mechanism. We also explored the roles of rennin-angiotensin system (RAS), extracellular signal-regulated kinases (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) in this process...
September 4, 2017: Molecular and Cellular Biochemistry
keyword
keyword
10488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"